Literature DB >> 29468608

Adjuvant Therapy in the Treatment of Melanoma.

Danielle M Bello1, Charlotte E Ariyan2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29468608     DOI： 10.1245/s10434-018-6376-y

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN： 1068-9265            Impact factor:   5.344


× No keyword cloud information.
  2 in total

1.  Nivolumab versus placebo as adjuvant therapy for resected stage III melanoma: a propensity weighted indirect treatment comparison and number needed to treat analysis for recurrence-free survival and overall survival.

Authors:  Jeffrey S Weber; Tayla Poretta; Brian D Stwalley; Leon A Sakkal; Ella X Du; Travis Wang; Yan Chen; Yan Wang; Keith A Betts; Alexander N Shoushtari
Journal:  Cancer Immunol Immunother       Date:  2022-10-05       Impact factor: 6.630

2.  Indirect Treatment Comparison of Nivolumab Versus Observation or Ipilimumab as Adjuvant Therapy in Resected Melanoma Using Pooled Clinical Trial Data.

Authors:  Morganna Freeman; Keith A Betts; Shan Jiang; Ella X Du; Komal Gupte-Singh; Yichen Lu; Sumati Rao; Alexander N Shoushtari
Journal:  Adv Ther       Date:  2019-08-22       Impact factor: 3.845
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.